As of 2025-10-16, the EV/EBITDA ratio of Recursion Pharmaceuticals Inc (RXRX) is -4.20. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RXRX's latest enterprise value is 2,445.72 mil USD. RXRX's TTM EBITDA according to its financial statements is -581.79 mil USD. Dividing these 2 quantities gives us the above RXRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.7x - 13.4x | 11.0x |
| Forward P/E multiples | 12.1x - 20.4x | 16.2x |
| Fair Price | (15.06) - (16.80) | (17.14) |
| Upside | -321.8% - -347.4% | -352.4% |
| Date | EV/EBITDA |
| 2025-10-15 | -4.20 |
| 2025-10-14 | -3.53 |
| 2025-10-13 | -3.26 |
| 2025-10-10 | -3.11 |
| 2025-10-09 | -3.55 |
| 2025-10-08 | -3.68 |
| 2025-10-07 | -3.04 |
| 2025-10-06 | -3.26 |
| 2025-10-03 | -3.23 |
| 2025-10-02 | -3.26 |
| 2025-10-01 | -2.94 |
| 2025-09-30 | -2.78 |
| 2025-09-29 | -2.80 |
| 2025-09-26 | -2.66 |
| 2025-09-25 | -2.59 |
| 2025-09-24 | -2.78 |
| 2025-09-23 | -2.73 |
| 2025-09-22 | -2.85 |
| 2025-09-19 | -2.80 |
| 2025-09-18 | -2.82 |
| 2025-09-17 | -2.65 |
| 2025-09-16 | -2.75 |
| 2025-09-15 | -2.70 |
| 2025-09-12 | -2.74 |
| 2025-09-11 | -2.76 |
| 2025-09-10 | -2.52 |
| 2025-09-09 | -2.64 |
| 2025-09-08 | -2.58 |
| 2025-09-05 | -2.58 |
| 2025-09-04 | -2.51 |
| 2025-09-03 | -2.59 |
| 2025-09-02 | -2.61 |
| 2025-08-29 | -2.64 |
| 2025-08-28 | -2.77 |
| 2025-08-27 | -2.79 |
| 2025-08-26 | -2.74 |
| 2025-08-25 | -2.74 |
| 2025-08-22 | -2.82 |
| 2025-08-21 | -2.70 |
| 2025-08-20 | -2.70 |
| 2025-08-19 | -2.94 |
| 2025-08-18 | -3.26 |
| 2025-08-15 | -3.44 |
| 2025-08-14 | -3.35 |
| 2025-08-13 | -3.39 |
| 2025-08-12 | -3.17 |
| 2025-08-11 | -3.08 |
| 2025-08-08 | -3.14 |
| 2025-08-07 | -3.17 |
| 2025-08-06 | -3.23 |